[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$PTRN $WBI $ALHC $COLD $ACGL $ARDT $APP $BILI $CNC $CI $CRCL $CHRD $CRH $CVS $DVN $DNTH $ECL $ELV $ZGN $GPOR $HUM $IMVT $INR $MOH $OSCR $OVV $PPTA $RNR $SNTI $SPXC $UNH $UPB -- THE WSJ"
X Link @notreload_ai 2025-10-14T13:56Z 2937 followers, XXX engagements
"+Initiations 10/14: $ALHC $APP $BILI $CHRD $CI $CORZ $CRCL $CRH $CVS $DNTH $DVN $ECL $FDX $HCA $HPK $INR $MNMD $PPTA $PTRN $REPX $RIOT $SNTI $SPXC $SVRA $THC $UNH $UPB $WAY $WBI $WULF $ZGN . -Initiations 10/14: $ACGL $CNC $HUM $RNR"
X Link @OpenOutcrier 2025-10-14T13:09Z 80K followers, 2235 engagements
"Truist🏁 $DNTH Buy/$56 $ARGX $AZN NVS JNJ IMVT CABA Truist said in its initiation report: Dianthus' differentiated approach to targeting the autoantibody mediated complement cascade (C1s inhibition) may offer similar efficacy as available complement (C5) inhibitors but with a cleaner safety profile. The recent Ph X proof-of-concept (PoC) results with claseprubart in generalized myasthenia gravis (gMG) were overall supportive of this thesis. In our view gMG data are also relatively de-risking for the ongoing Ph X chronic inflammatory demyelinating polyneuropathy (CIDP) trial for which we see"
X Link @Quantumup1 2025-10-14T10:43Z 3834 followers, 1422 engagements
"Just do DD found out on ORIS $DBTX $DBVT $DC $D $DCFC $DCGO $DCTH $DDC $DDI $DDL $DERM $DEVS $DFLI $DGHI $DGLY $DHAI $DHX $DIBS $DIT $DJCO $DLA $DLHC $DLNG $DLPN $DLTH $DM $DMAC $DMK $DMN $DMS $DMTK $DNA $DNMR $DNTH $DOGZ $DOMA $DOUG $DOYU $DPRO $DPSI"
X Link @SeegerErik 2025-10-12T20:01Z 1722 followers, XXX engagements